E. Fougera & Co. will celebrate its sesquicentennial this year, the Long Island, NY-based generic pharmaceuticals company announced.
E. Fougera & Co. will celebrate its sesquicentennial this year, the Long Island, NY-based generic pharmaceuticals company announced.
The company kicked off its celebration by donating two $2,500 grants to pharmacy degree programs at two local colleges, The Arnold and Marie Schwartz College of Pharmacy at Long Island University and the College of Pharmacy and Allied Health Professionals at St. John's University. The gifts will be used to support students who demonstrate academic achievement, financial need and service to the profession and/or the community.
The company, one of Long Island's largest employers, has always had local ties. Edmond Fougera, a French immigrant, founded it in Brooklyn in 1849. His business began as a pharmacy specializing in European imports and was the first pharmacy to introduce Americans to petroleum jelly.
By 1918, it developed a reputation as the country's "largest wholesale importing house for French and other foreign medicinal preparations and specialties," according to a 1918 article in The Brooklyn Eagle, the local news rag.
In the 1930s and 1940s, Fougera began specializing in the dermatological and urological markets, and it deployed a national sales force. By 1963, the company had attracted the attention of a German company called Byk Gulden GMBH, and the German company acquired Fougera. In 1966, the company entered the generic pharmaceutical market.
Over the course of the past 30 years, Fougera has focused on manufacturing and selling generic creams and ointments, such as Surgilube, Diflorasone Diacetate Cream, Hydrocortisone Rx and Vitamin A & D Ointment. Five of its products are ranked first in market share.
"If you open your medicine cabinet, chances are you will find a Fougera product right there on the shelf," said Stuart Schansinger, the company's buying group sales manager. "We are extremely proud of what we have achieved over our long history, from our roots as a retail pharmacy to our present role as a major generic pharmaceutical manufacturer." PR
Key Findings of the NIAGARA and HIMALAYA Trials
November 8th 2024In this episode of the Pharmaceutical Executive podcast, Shubh Goel, head of immuno-oncology, gastrointestinal tumors, US oncology business unit, AstraZeneca, discusses the findings of the NIAGARA trial in bladder cancer and the significance of the five-year overall survival data from the HIMALAYA trial, particularly the long-term efficacy of the STRIDE regimen for unresectable liver cancer.
Fake Weight Loss Drugs: Growing Threat to Consumer Health
October 25th 2024In this episode of the Pharmaceutical Executive podcast, UpScriptHealth's Peter Ax, Founder and CEO, and George Jones, Chief Operations Officer, discuss the issue of counterfeit weight loss drugs, the potential health risks associated with them, increasing access to legitimate weight loss medications and more.